NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

[X] 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).

[ ] 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

[ ] 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

[ ] 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

[ ] 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

[ ] 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

[ ] 7. Other: _____

Applicant Must Provide:

[X] An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".

[X] An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

[X] A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
PatentIn Software Program Support
    Technical Assistance.....................................703-287-0200
    To Purchase PatentIn Software.......................703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

```
        RAW SEQUENCE LISTING              DATE: 10/14/2000
        PATENT APPLICATION:  US/09/485,571    TIME: 18:30:34

        Input Set : A:\Breese-9.app
        Output Set: N:\CRF3\10132000\I485571.raw

     3 <110> APPLICANT: Calas, et al.
     5 <120> TITLE OF INVENTION: Linear peptides derived from antibiotic peptides,
     6       preparation and use for vectoring active substances
     8 <130> FILE REFERENCE: 19904-009 BREESE-9
    10 <140> CURRENT APPLICATION NUMBER: 09/485,571
    11 <141> CURRENT FILING DATE: 2000-06-09
    13 <150> PRIOR APPLICATION NUMBER: WO 99/07728
    14 <151> PRIOR FILING DATE: 1998-08-06
    16 <160> NUMBER OF SEQ ID NOS: 38
    18 <170> SOFTWARE: PatentIn Ver. 2.0
    20 <210> SEQ ID NO: 1
    21 <211> LENGTH: 18
    22 <212> TYPE: PRT
    23 <213> ORGANISM: Artificial Sequence
    25 <220> FEATURE:
    26 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
    27       synthesized
    29 <400> SEQUENCE: 1
    30 Arg Gly Gly Arg Leu Cys Tyr Cys Arg Arg Arg Phe Cys Val Cys Val
    31   1               5                  10                  15
    33 Gly Arg
    37 <210> SEQ ID NO: 2
    38 <211> LENGTH: 16
    39 <212> TYPE: PRT
    40 <213> ORGANISM: Artificial Sequence
    42 <220> FEATURE:
    43 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
    44       synthesized
    46 <400> SEQUENCE: 2
    47 Arg Gly Gly Arg Leu Cys Tyr Cys Arg Arg Arg Phe Cys Ile Cys Val
    48   1               5                  10                  15
    51 <210> SEQ ID NO: 3
    52 <211> LENGTH: 18
    53 <212> TYPE: PRT
    54 <213> ORGANISM: Artificial Sequence
    56 <220> FEATURE:
    57 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
    58       synthesized
    60 <400> SEQUENCE: 3
    61 Arg Gly Gly Gly Leu Cys Tyr Cys Arg Arg Arg Phe Cys Val Cys Val
    62   1               5                  10                  15
    64 Gly Arg
    68 <210> SEQ ID NO: 4
    69 <211> LENGTH: 18
    70 <212> TYPE: PRT
    71 <213> ORGANISM: Artificial Sequence
    73 <220> FEATURE:
```

RAW SEQUENCE LISTING   DATE: 10/14/2000
PATENT APPLICATION: US/09/485,571   TIME: 18:30:34

          Input Set : A:\Breese-9.app
          Output Set: N:\CRF3\10132000\I485571.raw

74 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
75   synthesized
77 <400> SEQUENCE: 4
78 Arg Gly Gly Arg Leu Cys Tyr Cys Arg Gly Trp Ile Cys Phe Cys Val
79 1   5   10   15
81 Gly Arg
85 <210> SEQ ID NO: 5
86 <211> LENGTH: 18
87 <212> TYPE: PRT
88 <213> ORGANISM: Artificial Sequence
90 <220> FEATURE:
91 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
92   synthesized
94 <400> SEQUENCE: 5
95 Arg Gly Gly Arg Leu Cys Tyr Cys Arg Pro Arg Phe Cys Val Cys Val
96 1   5   10   15
98 Gly Arg
102 <210> SEQ ID NO: 6
103 <211> LENGTH: 18
104 <212> TYPE: PRT
105 <213> ORGANISM: Artificial Sequence
107 <220> FEATURE:
108 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
109   synthesized
111 <400> SEQUENCE: 6
112 Arg Arg Trp Cys Phe Arg Val Cys Tyr Arg Gly Phe Cys Tyr Arg Lys
113 1   5   10   15
115 Cys Arg
119 <210> SEQ ID NO: 7
120 <211> LENGTH: 18
121 <212> TYPE: PRT
122 <213> ORGANISM: Artificial Sequence
124 <220> FEATURE:
125 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
126   synthesized
128 <400> SEQUENCE: 7
129 Arg Arg Trp Cys Phe Arg Val Cys Tyr Lys Gly Phe Cys Tyr Arg Lys
130 1   5   10   15
132 Cys Arg
136 <210> SEQ ID NO: 8
137 <211> LENGTH: 17
138 <212> TYPE: PRT
139 <213> ORGANISM: Artificial Sequence
141 <220> FEATURE:
142 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
143   synthesized
145 <400> SEQUENCE: 8
146 Lys Trp Cys Phe Arg Val Cys Tyr Arg Gly Ile Cys Tyr Arg Arg Cys
147 1   5   10   15

```
    149 Arg
    153 <210> SEQ ID NO: 9
    154 <211> LENGTH: 17
    155 <212> TYPE: PRT
    156 <213> ORGANISM: Artificial Sequence
    158 <220> FEATURE:
    159 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
    160       synthesized
    162 <400> SEQUENCE: 9
    163 Arg Trp Cys Phe Arg Val Cys Tyr Arg Gly Ile Cys Tyr Arg Lys Cys
    164   1               5                   10                  15
    166 Arg
    170 <210> SEQ ID NO: 10
    171 <211> LENGTH: 17
    172 <212> TYPE: PRT
    173 <213> ORGANISM: Artificial Sequence
    175 <220> FEATURE:
    176 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
    177       synthesized
    179 <400> SEQUENCE: 10
    180 Lys Trp Cys Phe Arg Val Cys Tyr Arg Gly Ile Cys Tyr Lys Arg Cys
    181   1               5                   10                  15
    183 Arg
    187 <210> SEQ ID NO: 11
    188 <211> LENGTH: 18
    189 <212> TYPE: PRT
    190 <213> ORGANISM: Artificial Sequence
    192 <220> FEATURE:
    193 <221> NAME/KEY: VARIANT
    194 <222> LOCATION: (1)..(18)
    195 <223> OTHER INFORMATION: Xaa may be the amino acids as defined in the spec
    197 <220> FEATURE:
    198 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
    199       synthesized
    201 <400> SEQUENCE: 11
W--> 202 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
    203   1               5                   10                  15
W--> 205 Xaa Xaa
    209 <210> SEQ ID NO: 12
    210 <211> LENGTH: 18
    211 <212> TYPE: PRT
    212 <213> ORGANISM: Artificial Sequence
    214 <220> FEATURE:
    215 <221> NAME/KEY: VARIANT
    216 <222> LOCATION: (1)..(18)
    217 <223> OTHER INFORMATION: Xaa may be the amino acids as defined in the spec
    219 <220> FEATURE:
    220 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
    221       synthesized
```

```
                    RAW SEQUENCE LISTING                DATE: 10/14/2000
                    PATENT APPLICATION:  US/09/485,571   TIME: 18:30:34

                    Input Set : A:\Breese-9.app
                    Output Set: N:\CRF3\10132000\I485571.raw

       223 <400> SEQUENCE: 12
W--> 224 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
     225  1                  5                 10                15
W--> 227 Xaa Xaa
       231 <210> SEQ ID NO: 13
       232 <211> LENGTH: 18
       233 <212> TYPE: PRT
       234 <213> ORGANISM: Artificial Sequence
       236 <220> FEATURE:
       237 <221> NAME/KEY: VARIANT
       238 <222> LOCATION: (1)..(18)
       239 <223> OTHER INFORMATION: Xaa may be the amino acids as defined in the spec
       241 <220> FEATURE:
       242 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
       243        synthesized
       245 <400> SEQUENCE: 13
W--> 246 Arg Xaa Xaa Arg Xaa Xaa Xaa Xaa Arg Arg Arg Xaa Xaa Xaa Xaa Xaa
     247  1                  5                 10                15
W--> 249 Xaa Arg
       253 <210> SEQ ID NO: 14
       254 <211> LENGTH: 18
       255 <212> TYPE: PRT
       256 <213> ORGANISM: Artificial Sequence
       258 <220> FEATURE:
       259 <221> NAME/KEY: VARIANT
       260 <222> LOCATION: (1)..(18)
       261 <223> OTHER INFORMATION: Xaa may be the amino acids as defined in the spec.
       263 <220> FEATURE:
       264 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
       265        synthesized
       267 <400> SEQUENCE: 14
W--> 268 Arg Arg Xaa Xaa Xaa Arg Xaa Xaa Xaa Arg Xaa Xaa Xaa Xaa Arg Arg
     269  1                  5                 10                15
W--> 271 Xaa Arg
       275 <210> SEQ ID NO: 15
       276 <211> LENGTH: 18
       277 <212> TYPE: PRT
       278 <213> ORGANISM: Artificial Sequence
       280 <220> FEATURE:
       281 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
       282        synthesized
       284 <400> SEQUENCE: 15
       285 Arg Gly Gly Arg Leu Ser Tyr Ser Arg Arg Arg Phe Ser Val Ser Val
     286  1                  5                 10                15
       288 Gly Arg
       292 <210> SEQ ID NO: 16
W--> 293 <400> SEQUENCE: 16
W--> 294 .000
       296 <210> SEQ ID NO: 17
```

```
                    RAW SEQUENCE LISTING              DATE: 10/14/2000
                    PATENT APPLICATION:  US/09/485,571   TIME: 18:30:34

                    Input Set : A:\Breese-9.app
                    Output Set: N:\CRF3\10132000\I485571.raw

297 <211> LENGTH: 18
298 <212> TYPE: PRT
299 <213> ORGANISM: Artificial Sequence
301 <220> FEATURE:
302 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
303        synthesized
305 <400> SEQUENCE: 17
306 Arg Gly Val Ser Val Ser Phe Arg Arg Arg Ser Tyr Ser Leu Arg Gly
307  1               5                  10                  15
309 Gly Arg
313 <210> SEQ ID NO: 18
314 <211> LENGTH: 18
315 <212> TYPE: PRT
316 <213> ORGANISM: Artificial Sequence
318 <220> FEATURE:
319 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
320        synthesized
322 <400> SEQUENCE: 18
323 Glu Gly Gly Glu Leu Ser Tyr Ser Glu Glu Glu Phe Ser Val Ser Val
324  1               5                  10                  15
326 Gly Glu
330 <210> SEQ ID NO: 19
331 <211> LENGTH: 18
332 <212> TYPE: PRT
333 <213> ORGANISM: Artificial Sequence
335 <220> FEATURE:
336 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
337        synthesized
339 <400> SEQUENCE: 19
340 Arg Gly Gly Arg Leu Ala Tyr Arg Leu Leu Arg Phe Ala Ile Arg Val
341  1               5                  10                  15
343 Gly Arg
347 <210> SEQ ID NO: 20
348 <211> LENGTH: 18
349 <212> TYPE: PRT
350 <213> ORGANISM: Artificial Sequence
352 <220> FEATURE:
353 <221> NAME/KEY: VARIANT
354 <222> LOCATION: (1)..(18)
355 <223> OTHER INFORMATION: Xaa may be the amino acids as defined in the spec.
357 <220> FEATURE:
358 <223> OTHER INFORMATION: Description of Artificial Sequence: chemically
359        synthesized
361 <400> SEQUENCE: 20
362 Xaa Gly Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
363  1               5                  10                  15
365 Xaa Gly
369 <210> SEQ ID NO: 21
370 <211> LENGTH: 18
```

Please Note:
Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

VERIFICATION SUMMARY   ·DATE: 10/14/2000
· PATENT APPLICATION: US/09/485,571   TIME: 18:30:35

Input Set : A:\Breese-9.app
Output Set: N:\CRF3\10132000\I485571.raw

```
L:11  M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:202 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:205 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:224 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12
L:227 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12
L:246 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13
L:249 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13
L:268 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14
L:271 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14
L:293 M:283 W: Missing Blank Line separator, <400> field identifier
L:294 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (16) SEQUENCE:
L:362 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20
L:365 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20
L:384 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:21
L:485 M:283 W: Missing Blank Line separator, <400> field identifier
L:486 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (28) SEQUENCE:
L:489 M:283 W: Missing Blank Line separator, <400> field identifier
L:490 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (29) SEQUENCE:
L:524 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:527 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:566 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:585 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:34
L:607 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35
L:610 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35
L:629 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36
L:651 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:37
L:674 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38
L:677 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38
```